Is bupropion safe for use while breastfeeding?

Bupropion Use During Breastfeeding: Proceed with Caution

Bupropion can be used during breastfeeding, but caution is advised due to limited data and two case reports of seizures in breastfed infants. While the drug is present in breast milk at very low levels (average infant exposure of 2% of maternal weight-adjusted dose), and most infants have shown no adverse effects, the potential for serious neurological events requires careful monitoring 1, 2.

Evidence Quality and Recommendations

The most recent 2024 guideline from the American Journal of Obstetrics and Gynecology explicitly states "Overall—caution is advised" for bupropion during breastfeeding 1. This recommendation is based on:

• Very limited data (only 21 documented cases)
• Bupropion and metabolites are detectable in infant serum, though at very low levels (sometimes undetectable)
• Two case reports of seizures in breastfed infants exposed to bupropion 1, 3

The FDA drug label corroborates this, noting that while postmarketing reports have described seizures in breastfed infants, "the relationship of bupropion exposure and these seizures is unclear" 2.

Pharmacokinetic Data

Research demonstrates that bupropion transfer into breast milk is relatively low:

• Average daily infant exposure is 2% of maternal weight-adjusted dose 2, 4
• When including active metabolites, total infant exposure reaches approximately 2% on a molar basis 4
• Milk-to-plasma ratios range from 2.51 to 8.58, indicating concentration in breast milk 5
• In two mother-infant pairs, neither infant had quantifiable serum levels of bupropion or hydroxybupropion at steady state 6

Critical Safety Considerations

The Seizure Risk

The most concerning finding is the documented seizure cases:

1. One case involved a 6.5-month-old infant exposed to both bupropion (150 mg/day) and escitalopram who presented with severe emesis and tonic seizure-like symptoms 3

   • Seizures occurred at serum concentrations below the therapeutic range, suggesting infants may have higher susceptibility to bupropion's epileptogenic effects
   • Drug interaction with escitalopram (via CYP2D6 inhibition) may have contributed

2. Second case reported in the literature without detailed documentation 7

When Bupropion May Be Considered

The 2024 guideline suggests bupropion as a potential option during the perinatal period, particularly for:

• Women requiring treatment for co-occurring depression and ADHD 1
• Those attempting smoking cessation during the postpartum period 4
• Patients who have responded well to bupropion and require continued treatment 1

Clinical Decision-Making Algorithm

If bupropion is deemed necessary:

1. Assess maternal need: Is bupropion essential for maternal functioning? Are safer alternatives (e.g., sertraline, paroxetine) inadequate?

2. Use lowest effective dose: The guideline recommends maintaining therapeutic dose if needed, but consider whether dose reduction is feasible 1

3. Implement monitoring protocol:

   • Advise mother to observe infant for drowsiness, poor feeding, and any seizure-like activity
   • Monitor infant weight gain and developmental milestones closely 1
   • Consider more frequent pediatric follow-up visits

4. Timing strategies: While not extensively studied for bupropion, timing breastfeeding to occur when milk concentrations are lowest may reduce infant exposure

5. Document informed consent: Ensure mother understands the limited data and potential seizure risk

Comparison to Preferred Alternatives

The evidence strongly suggests that SSRIs like sertraline and paroxetine are safer first-line options during breastfeeding, with more extensive safety data and lower risk profiles 8. Bupropion should be reserved for situations where:

• SSRIs have failed or are contraindicated
• Maternal depression is complicated by ADHD symptoms
• Smoking cessation is a concurrent treatment goal

Common Pitfalls to Avoid

1. Don't assume "low levels = no risk": The seizure cases occurred despite low serum concentrations in infants
2. Don't overlook drug interactions: Polypharmacy (especially with other CYP2D6 inhibitors) may increase risk 3
3. Don't fail to counsel: The limited data means uncertainty exists—mothers must understand this
4. Don't forget metabolites: Hydroxybupropion is active and more potent than the parent drug; it accumulates in milk 5

Bottom Line

Bupropion during breastfeeding requires a careful risk-benefit analysis prioritizing maternal mental health needs against potential infant neurological risks. The 2024 guideline's "caution advised" designation, combined with FDA warnings about seizures, means this medication should not be a first-line choice when safer alternatives exist. However, for women who require bupropion for optimal functioning, breastfeeding can continue with vigilant infant monitoring for signs of adverse effects, particularly neurological symptoms 1, 2.